Glass Lewis & Co. Recommends Renovis Shareholders Vote For Merger With Evotec
April 22 2008 - 9:30AM
PR Newswire (US)
SOUTH SAN FRANCISCO, April 22 /PRNewswire-FirstCall/ -- Renovis,
Inc. (NASDAQ:RNVS), today announced that Glass Lewis & Co., a
leading proxy advisory firm, has joined ISS/Risk Metrics in
recommending that Renovis stockholders vote "FOR" the merger
agreement with Evotec AG (Frankfurt Stock Exchange: EVT) at the
Special Stockholders Meeting scheduled for May 1, 2008. In the
proposed merger, each share of Renovis common stock will be
converted into the right to receive the equivalent of 1.0542 Evotec
ordinary shares. The Board of Directors of Renovis unanimously
recommends that stockholders vote "FOR" the approval and adoption
of the agreement and plan of merger, and the approval of the merger
and related transactions as described in the proxy
statement/prospectus. The company encourages all stockholders to
vote their shares promptly by phone, Internet, or by mailing their
proxy card, and to contact MacKenzie Partners at 800/322-2885 or
collect at 212/929-5500 if they have any questions or need any
assistance in voting their shares. About Renovis Renovis is a
biopharmaceutical company focused on the discovery and development
of drugs for major medical needs in the areas of neurological and
inflammatory diseases. The Company's proprietary research programs
focus on the purinergic receptors, P2X3 and P2X7, for the potential
treatment of pain and inflammatory diseases. In addition, Renovis
has a worldwide collaboration and license agreement with Pfizer to
research, develop and commercialize small molecule vanilloid
receptor (VR1). For additional information about the company,
please visit http://www.renovis.com/. Forward-Looking Statements
This communication contains certain forward-looking statements. All
statements, other than statements of historical facts, regarding
the likelihood and timing of the completion of the business
combination transaction involving Evotec and Renovis, the
conversion of Renovis shares into a right to receive Evotec shares,
the anticipated benefits of such transaction and the plans and
objectives of management are forward-looking statements and are
based on management's current expectations and estimates. We may
not actually achieve these plans, intentions or expectations and
Renovis cautions investors not to place undue reliance on our
forward-looking statements. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
the forward-looking statements we make. Factors that could cause or
contribute to such differences may include, but are not limited to,
risks relating to the integration of the technologies and
businesses of Evotec and Renovis, unanticipated expenditures,
changing relationships with customers, suppliers and strategic
partners, conditions of the economy and other factors described in
the Registration Statement on Form F-4 filed with the SEC by Evotec
and the most recent reports on Form 10-K, Form 10-Q, Form 8-K and
other periodic reports filed by Renovis with the SEC. Additional
information about the transaction Renovis filed a Current Report on
Form 8-K with the Securities and Exchange Commission on September
24, 2007, that includes as an exhibit the Agreement and Plan of
Merger between Evotec and Renovis. Evotec and Renovis have mailed a
joint proxy statement/prospectus to stockholders of Renovis in
connection with the proposed merger. This document contains
important information about the merger and should be read before
any decision is made with respect to the merger. Investors and
stockholders will be able to obtain free copies of this document
and any other documents filed or furnished by Evotec or Renovis
through the website maintained by the Securities and Exchange
Commission at http://www.sec.gov/. Free copies of these documents
may also be obtained from Renovis by directing a request to
Renovis' Investor Relations department at Two Corporate Drive,
South San Francisco, California 94080 or from Evotec by directing a
request to Evotec's Investor Relations department at
Schnackenburgallee 114, 22525 Hamburg, Germany. In addition to the
documents referenced above, Renovis files or furnishes annual,
quarterly and current reports, proxy statements and other
information with the Securities and Exchange Commission. You may
read and copy any reports, statements or other information filed or
furnished by Renovis at the SEC's Public Reference Room at Station
Place, 100 F Street, N.E., Washington, D.C. 20549. You can request
copies of these documents by writing to the SEC and paying a fee
for the copying cost. Please call the SEC at 1-800-SEC-0330 for
more information about the operation of the Public Reference Room.
Renovis's SEC filings are also available to the public at the SEC's
web site at http://www.sec.gov/, or at http://www.renovis.com/.
Participants in Solicitations Renovis and its directors, executive
officers and other members of its management and employees may be
deemed to be participants in the solicitation of proxies from
stockholders of Renovis in connection with the merger. Information
regarding Renovis's directors and executive officers is available
in the joint proxy statement/prospectus, which has been mailed to
stockholders of Renovis in connection with the proposed merger
proxy statement, and the other relevant documents filed with the
SEC. DATASOURCE: Renovis, Inc. CONTACT: Shari Annes of Renovis,
Inc., +1-650-888-0902, Web site: http://www.renovis.com/
Copyright
Renovis (MM) (NASDAQ:RNVS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Renovis (MM) (NASDAQ:RNVS)
Historical Stock Chart
From Oct 2023 to Oct 2024